Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biovest International
Biovest receives rare designation from European drug agency for cancer therapy
November 7th, 2006
A majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., (ABPI), Biovest International, Inc., (BVTI) has received notification from the Commission of the European Union on its acceptance of Biovest's BiovaxID therapy for Follicular Lymphoma for entry into the European Community's Drug Register for Rare Diseases. This designation significant offers benefits to Biovest in its development and marketing of BiovaxID in the European Union (E.U.). This acceptance follows the previously announced recommendation by the Committee on Orphan Medical Products (COMP) of the European Medicines Agency that BiovaxID be granted designation as a treatment for...
Source: Drug Law Weekly (2006-11-07)
|
